265 results
Page 4 of 14
425
jie256ja
5 Dec 22
Business combination disclosure
9:28am
8-K
f0hs3
5 Dec 22
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
9:27am
8-K
EX-99.1
ibc52x vvxf36
5 Dec 22
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
9:27am
424B3
3cens0 hyjaykre
5 Dec 22
Prospectus supplement
9:22am
425
zlgv7hw9qmmjm2kp
1 Dec 22
Business combination disclosure
4:04pm
8-K
spql8f6 ckz
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
425
mr2sctmj471gyo
29 Nov 22
Business combination disclosure
4:03pm
8-K
trocdcmagni7gk0io
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
qyca9opxi mm5phd
28 Nov 22
Business combination disclosure
4:03pm
8-K
rmrxrp4
28 Nov 22
Regulation FD Disclosure
4:01pm
425
j7dp 1xamu
15 Nov 22
Business combination disclosure
4:03pm
8-K
qib flvzpdkd56iv3cm1
15 Nov 22
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
4:02pm
425
b6b7nkn0efnr6mso8
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.1
tr58ayk 67qreiq2
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
8-K
iz3t679xx3i qwjqstc2
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
8-K
EX-99.2
8mj sudt2yvcgfg0u61
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
424B3
vjerw626
10 Nov 22
Prospectus supplement
4:21pm
425
us1hiuh5 sec39eq5j3u
27 Oct 22
Business combination disclosure
7:15am